Etiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) in Japan

Pulmonary Disease, Chronic Obstructive Clinical Trial

Official title:

A Prospective, Epidemiological, Cohort Study to Assess the Aetiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Japan

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03957577
• Other study ID #: 208636
• Status: Completed
• Start date: June 13, 2019
• Est. completion date: June 30, 2022

Study information

• Verified date: February 2024
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this prospective, epidemiological, cohort study is to evaluate the lung microbiome in stable-state chronic obstructive pulmonary disease (COPD) in Japanese participants

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: June 30, 2022
• Est. primary completion date: June 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Participants must be able and willing to comply with the requirements of the protocol.

• Participant must be aged greater than or equal to (>=)40 years to to less than or equal to (<=)80 years at the time of signing the informed consent form (ICF).

• Participants must have a record of a clinical diagnosis of COPD, ACOS or CB.

• Participants must have moderate to severe airflow limitation based on spirometry: FEV1 percent predicted normal >=30 to <=80 percent (%) and post-bronchodilator FEV1/forced vital capacity (FVC) ratio <0.7.

• Participants must be symptomatic at Screening, defined as having a CAT score >=10.

• Participants must have a documented history of at least 1 LRTI treated with antibiotics and/or oral/systemic corticosteroids.

• Participants must be current or former tobacco (cigarette) smokers with a smoking history of >=10 pack-years.

• Participants may be male or female. For female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding. Women of non-childbearing potential can also participate. A woman of childbearing potential must have had a highly sensitive negative urine pregnancy test.

• Participants should be able to provide a spontaneous or induced sputum sample of >=0.2 grams (g) at the Screening Visit.

Exclusion Criteria:

• Participants with a diagnosed respiratory disorder other than COPD, ACOS or CB.

• Participants with a diagnosis of alpha-1 antitrypsin deficiency as the underlying cause of COPD.

• Participants who have received antibiotics within 1 month of Screening or have received antibiotics for more than 30 days within 90 days prior to Screening; Except for those who have received and are currently receiving long-term treatment with low-dose macrolide: erythromycin <=600 milligrams (mg) per (/) day or clarithromycin <=200 mg/day.

• Participants who have received systemic corticosteroids (oral/intravenous/intramuscular) for more than 14 consecutive days within 90 days prior to giving informed consent.

• Participants who are unable to use or to comply with daily completion of the eDiary.

Related Conditions & MeSH terms

• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Other:
• Prospective observational cohort study
Prospective observational cohort study

Locations

Country	Name	City	State
Japan	GSK Investigational Site	Fukuoka
Japan	GSK Investigational Site	Fukuoka
Japan	GSK Investigational Site	Fukuoka
Japan	GSK Investigational Site	Fukushima
Japan	GSK Investigational Site	Hiroshima
Japan	GSK Investigational Site	Mie
Japan	GSK Investigational Site	Nagasaki
Japan	GSK Investigational Site	Niigata
Japan	GSK Investigational Site	Osaka
Japan	GSK Investigational Site	Osaka
Japan	GSK Investigational Site	Osaka
Japan	GSK Investigational Site	Shizuoka
Japan	GSK Investigational Site	Tokyo

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with first evaluable moderate or severe AECOPD that have infectious or non-infectious etiology		Up to Month 12
Primary	Microbiome composition of sputum in stable-state COPD as measured by bacterial ribosomal ribonucleic acid (rRNA) sequencing		Baseline (Screening visit or Month 0)
Secondary	Number of all-cause moderate and severe AECOPD per participants		Up to Month 12
Secondary	Microbiome composition of sputum in stable-state COPD as measured by bacterial rRNA sequencing		Baseline (Screening visit or Month 0)
Secondary	Microbiome composition of sputum during participant's first evaluable moderate or severe AECOPD		Up to Month 12
Secondary	Number of participants with first evaluable sputum samples that are positive for potentially pathogenic viruses (overall and by species) and bacteria in stable state COPD as measured by bacterial culture or quantitative polymerase chain reaction (qPCR)		Baseline (Screening visit or Month 0)
Secondary	Number of participants with first evaluable sputum samples that are positive for potentially pathogenic viruses (overall and by species) and bacteria during moderate or severe AECOPD as measured by bacterial culture or qPCR		Baseline (Screening visit or Month 0)
Secondary	Number of EXACT events per participant over the course of 12 months	An EXACT event is defined as an increase in EXACT score more than or equal to 12 points for 2 days or more than or equal to 9 points for 3 days, above the participant's mean Baseline score. Severity is indicated by the worst (i.e., highest) EXACT total score during the course of the event.	Up to Month 12
Secondary	Number of AECOPD events		Up to Month 12
Secondary	Severity of AECOPD according to healthcare utilization		Up to Month 12
Secondary	Severity of EXACT events according to EXACT total score		Up to Month 12
Secondary	Duration of AECOPD		Up to Month 12
Secondary	Duration of EXACT events		Up to Month 12
Secondary	Mean change in CAT score between stable-state COPD and participants' first evaluable moderate or severe AECOPD	The CAT is a 8-item, participant-completed instrument that covers symptoms such as cough, phlegm, chest tightness and breathlessness, and disease impacts including physical activity, confidence, sleep and energy. Participants will be asked to score each item on a scale ranging from 0 (no symptom or impact at all) to 5 (maximal symptom or impact).	Baseline (Screening visit or Month 0) and up to Month 12
Secondary	Mean change in CAT score over the course of 1 year	The CAT is a 8-item, participant-completed instrument that covers symptoms such as cough, phlegm, chest tightness and breathlessness, and disease impacts including physical activity, confidence, sleep and energy. Participants will be asked to score each item on a scale ranging from 0 (no symptom or impact at all) to 5 (maximal symptom or impact).	Baseline (Screening visit or Month 0) and up to Month 12
Secondary	Mean change in EXACT score	EXACT is a validated, self-administered, 14-item daily diary that assesses 11 respiratory symptoms and 3 additional symptoms, which together characterize COPD exacerbations. The EXACT total score will range from 0 to 100, with higher scores indicating a more severe condition.	Baseline(Screening visit or Month 0) and up to Month 12
Secondary	Mean change in E-RS COPD total and subscale scores between stable-state COPD and participants' first evaluable moderate or severe AECOPD	The E-RS: COPD comprises 11 of the 14 items of the parent EXACT that are specifically related to respiratory symptoms and will be completed using the eDiary. The RS-Total score is computed by taking the sum of the items comprising the instrument, with scores ranging from 0 to 40, with higher scores indicating more severe respiratory symptoms.	Baseline (Screening visit or Month 0) and up to Month 12
Secondary	Mean change in E-RS: COPD total and subscale scores over the course of 1 year	The E-RS: COPD comprises 11 of the 14 items of the parent EXACT that are specifically related to respiratory symptoms and will be completed using the eDiary. The RS-Total score is computed by taking the sum of the items comprising the instrument, with scores ranging from 0 to 40, with higher scores indicating more severe respiratory symptoms.	Baseline (Screening visit or Month 0) and up to Month 12
Secondary	Mean change in Forced expiratory volume in 1 second (FEV1) between stable-state COPD, during participants' first evaluable moderate or severe AECOPD		Baseline (Screening visit or Month 0) and up to month 12
Secondary	Mean rate of AECOPD related healthcare resource utilization per participant		Up to Month 12
Secondary	Mean rate of non-AECOPD related healthcare resource utilization per participant		Up to Month 12
Secondary	Annual rate of AECOPD related healthcare resource utilization per participant		Up to Month 12
Secondary	Annual rate of non-AECOPD related healthcare resource utilization per participant		Up to Month 12